You are here: Industry Insights > Novartis

News List

Novartis brings in GlaxoSmithKline's Richard Saynor to lead turnaround of Sandoz unit firstwordpharma
April 25, 2019
Novartis announced Wednesday alongside its first-quarter financial results, that Richard Saynor, the current senior vice president of classic and established products, commercial and digital platforms at GlaxoSmithKline.
Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting firstwordpharma
April 25, 2019
Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD).
Novartis lifts annual profit outlook as Cosentyx, Entresto lead first-quarter sales growth firstwordpharma
April 25, 2019
Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off and strong operational execution leading us to revise 2019 profit guidance upwards ...
Novartis brings in GlaxoSmithKline's Richard Saynor to lead turnaround of Sandoz unit firstwordpharma
April 25, 2019
Novartis announced Wednesday alongside its first-quarter financial results, that Richard Saynor, the current senior vice president of classic and established products ...
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy pharmafile
April 23, 2019
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in the treatment...
New data reinforce effectiveness of Novartis’ Zolgensma for SMA pharmatimes
April 21, 2019
New AveXis data has reinforced the effectiveness of Novartis’ spinal muscular atrophy (SMA) Type I drug, Zolgensma (onasemnogene abeparvovec-xioi).
Novartis' speedy brolucizumab review tees up battle with Eylea, Lucentis fiercepharma
April 18, 2019
Look out, Roche and Regeneron—Novartis eye candidate brolucizumab is on its way.
Novartis’ wet AMD drug gets FDA filing pharmatimes
April 18, 2019
The governing body accepted the company's Biologics License Application, meaning that Novartis is now seeking to ……
New data reinforce effectiveness of Novartis’ Zolgensma for SMA pharmatimes
April 18, 2019
The Phase III STR1VE data show prolonged event-free survival, early and rapid increases in The Children's Hospital of ……
Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD drugs
April 17, 2019
Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page